 Interleukin-2
"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
| Descriptor ID |
D007376
|
| MeSH Number(s) |
D12.644.276.374.465.502 D12.644.276.374.480.372 D12.776.467.374.465.502 D12.776.467.374.480.372 D23.529.374.465.502 D23.529.374.480.372
|
| Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in UAMS Profiles by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2021 | 1 | 2 | 3 | | 2017 | 1 | 2 | 3 | | 2016 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2012 | 0 | 3 | 3 | | 2011 | 0 | 3 | 3 | | 2010 | 0 | 3 | 3 | | 2009 | 1 | 2 | 3 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2006 | 1 | 2 | 3 | | 2005 | 1 | 0 | 1 | | 2004 | 0 | 2 | 2 | | 2003 | 1 | 1 | 2 | | 2002 | 1 | 1 | 2 | | 2001 | 0 | 3 | 3 | | 2000 | 0 | 3 | 3 | | 1998 | 1 | 1 | 2 | | 1997 | 0 | 3 | 3 | | 1994 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1991 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles over the past ten years.
-
Mehta NK, Rakhra K, Meetze KA, Li B, Momin N, Chang JYH, Wittrup KD, Baeuerle PA, Michaelson JS. CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity. Cancer Immunol Res. 2024 Aug 01; 12(8):1022-1038.
-
Lozano-Ojalvo D, Tyler SR, Aranda CJ, Wang J, Sicherer S, Sampson HA, Wood RA, Burks AW, Jones SM, Leung DYM, de Lafaille MC, Berin MC. Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans. Allergy. 2023 03; 78(3):697-713.
-
Scott XO, Chen SH, Hadad R, Yavagal D, Peterson EC, Starke RM, Dietrich WD, Keane RW, de Rivero Vaccari JP. Cohort study on the differential expression of inflammatory and angiogenic factors in thrombi, cerebral and peripheral plasma following acute large vessel occlusion stroke. J Cereb Blood Flow Metab. 2022 10; 42(10):1827-1839.
-
Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, Pan H, Wu J, Brennan R, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana V, Santiago T, Hank JA, Gillies SD, Yu A, Sondel PM, Leung WH, Pappo A, Federico SM. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. J Clin Oncol. 2022 02 01; 40(4):335-344.
-
Safina I, Al Sudani ZAN, Hashoosh A, Darrigues E, Watanabe F, Biris AS, Dings RPM, Bao Vang K. Gold nanorods enhance different immune cells and allow for efficient targeting of CD4+ Foxp3+ Tregulatory cells. PLoS One. 2021; 16(8):e0241882.
-
Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021; 12:628063.
-
Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329.
-
Kim Wiese A, Schluterman Burdine M, Turnage RH, Tackett AJ, Burdine LJ. DNA-PKcs controls calcineurin mediated IL-2 production in T lymphocytes. PLoS One. 2017; 12(7):e0181608.
-
Jordan SJ, Gupta K, Ogendi BMO, Bakshi RK, Kapil R, Press CG, Sabbaj S, Lee JY, Geisler WM. The Predominant CD4+ Th1 Cytokine Elicited to Chlamydia trachomatis Infection in Women Is Tumor Necrosis Factor Alpha and Not Interferon Gamma. Clin Vaccine Immunol. 2017 Apr; 24(4).
-
Hirakawa M, Matos TR, Liu H, Koreth J, Kim HT, Paul NE, Murase K, Whangbo J, Alho AC, Nikiforow S, Cutler C, Ho VT, Armand P, Alyea EP, Antin JH, Blazar BR, Lacerda JF, Soiffer RJ, Ritz J. Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278.
-
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015 Oct; 73(4):645-54.
-
Atif SM, Lee SJ, Li LX, Uematsu S, Akira S, Gorjestani S, Lin X, Schweighoffer E, Tybulewicz VL, McSorley SJ. Rapid CD4+ T-cell responses to bacterial flagellin require dendritic cell expression of Syk and CARD9. Eur J Immunol. 2015 Feb; 45(2):513-24.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|